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Abstract
Background: The MRE11/RAD50/NBS1 (MRN) complex plays an essential role in detecting and repairing double-
stranded breaks, and thus the potential roles of MRE11, RAD50 and NBS1 proteins in the pathogenesis of various
cancers is the subject of investigation. This study was aimed at assessing the three-protein panel of MRN complex
subunits as a potential radiosensitivity marker and evaluating the prognostic and clinicopathological implications of
MRN expression in rectal cancer.
Methods: Samples from 265 rectal cancer patients treated with surgery and adjuvant chemoradiotherapy, including
samples from 55 patients who were treated with neoadjuvant radiotherapy between 2000 and 2011, were analyzed.
Expression of MRN complex proteins in tissue samples was determined by immunohistochemistry. Univariate and
multivariate analyses were carried out to identify clinicopathological characteristics that are associated with the
MRN three-protein panel expression in rectal cancer samples.
Results: In Kaplan–Meier survival analyses, we found that high level expression of MRN complex proteins in
postoperative samples was associated with poor disease-free (p = 0.021) and overall (P = 0.002) survival. Interestingly,
high MRN expression also correlated with poor disease-free (P = 0.047) and overall (P = 0.024) survival in the
neoadjuvant radiotherapy subgroup. In multivariate analysis, combined MRN expression (hazard ratio = 2.114, 95%
confidence interval 1.096–4.078, P = 0.026) and perineural invasion (hazard ratio = 2.160, 95% confidence interval 1.
209–3.859, P = 0.009) were significantly associated with a worse disease-free survival.
Conclusions: Expression levels of MRN complex proteins significantly predict disease-free survival in rectal cancer patients,
including those treated with neoadjuvant radiotherapy, and may have value in the management of these patients.
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Background
Colorectal cancer (CRC) is one of the most prevalent ma-
lignancies. Although CRC patient mortality rates are de-
creasing because of improved screening and treatment
methods, CRC remains the third most commonly diag-
nosed cancer in the United States [1] and the third most
important cause of cancer-related death globally [2]. Co-
lonic and rectal cancers are often combined as a single en-
tity in many studies but they differ in their metastatic
pattern, drug response, and optimal treatment methods
[3]. Rectal cancer patients experience poorer survival out-
comes than colon cancer patients because resection is
more difficult [4]; therefore, selection of appropriate treat-
ment is especially important for rectal cancer patients.
Neoadjuvant (i.e., preoperative) radiotherapy or che-
moradiation is routinely used to treat patients with rec-
tal cancer to improve surgical outcomes [3]. Many
studies have found that this therapy improves overall
survival (OS) and reduce recurrence [5, 6].
Meta-analyses have shown that neoadjuvant radiother-
apy improves local control [7], prevents recurrence [8],
and reduces mortality [9], but the effect on a given out-
come varies greatly between studies. This inconsistency
is due in part to the large variation in outcomes between
patients. Only 10–30% of patients show a complete re-
sponse to preoperative chemoradiation, and 70% show a
decrease in the tumor stage [10, 11]. Neoadjuvant radio-
therapy also has a significant risk of adverse effects in
rectal cancer patients, especially gastrointestinal disor-
ders such as bowel obstruction, abdominal pain, and
nausea [12]. Although these adverse effects have become
less prevalent as irradiation techniques have improved
[13], it remains important to select patients carefully for
radiotherapy to avoid unnecessary side effects.
Many studies have sought biomarkers that would pre-
dict the patient’s response to radiotherapy or chemora-
diotherapy, including imaging findings, gene mutations,
and expression levels of mRNAs and proteins [14]. The
radiosensitivity index (RSI) is a 10-gene signature that
predicts the response to radiotherapy in cell lines [15],
and has been shown to predict OS in glioblastoma pa-
tients [16]. A radioresistance (RadR) score calculated
based on expression of 13 genes was associated with re-
currence in head and neck squamous cell carcinoma pa-
tients treated with adjuvant radiotherapy [17]. More
than 40 potential molecular biomarkers have been
assessed for their ability to predict outcomes in rectal
cancer patients receiving neoadjuvant therapy, often
with conflicting results [14]. Therefore, there is still a
great need for simple, accurate biomarkers that will pre-
dict rectal cancer patient outcomes.
DNA damage repair has been described as a “double--
edged sword” in cancer [18]. Defective repair can lead to
genome instability and promote cancer formation.
Deficiencies in the mismatch repair (MMR) pathway, for
example, cause a hypermutability phenotype known as
microsatellite instability (MSI). This can lead to overall
genetic instability and mutations in many other genes
that promote cancer development and progression [19].
MSI is found in approximately 15% of rectal cancers
[20]. Conversely, DNA damage is also the mechanism by
which radiotherapy and some chemotherapy treatments
cause cancer cell death. Thus, cancer cells that can effi-
ciently repair the damage may become resistant to such
therapies. The link between DNA damage repair and
radiotherapy makes DNA damage-related proteins at-
tractive targets for developing new therapies and for
identifying markers of sensitivity to existing therapies.
For example, the levels of phosphorylated DNA damage
repair related proteins ATM and γH2AX have been
identified as biomarkers for radiosensitivity to 12C6+ ra-
diation in various tumor cell lines [21].
Radiotherapy causes double-stranded breaks (DSBs) in
DNA. The highly conserved MRN complex comprises the
MRE11, RAD50, and NBS1 proteins, and is one of the first
factors to sense and bind DSBs. The MRN complex can
physically tether DNA ends together, and also plays an en-
zymatic role in DNA repair via the nuclease activity of
MRE11 [22]. The cell cycle checkpoint kinase ATM is re-
cruited to DSBs and activated with the help of MRN, and
ATM then phosphorylates all three MRN subunits, dem-
onstrating a role of the complex in cell cycle progression
following DNA damage [23]. These roles of the MRN
complex led us to hypothesize that tumors deficient in the
MRN complex may be more sensitive to the
DNA-damaging effects of radiotherapy. We have previ-
ously shown that the combined expression of two protein
markers of MRE11 and ATM may be predictive of patient
outcomes in rectal cancer [24]. We have also found that
postoperative expression of RAD50 correlates to patient
outcomes in rectal cancer [25]. In the current paper, we
have extended our studies to include NBS1 and investi-
gated whether the combined expression of the MRN com-
plex proteins MRE11-RAD50-NBS1 may be superior in
predicting patient outcomes after radiotherapy, and there-




The study was conducted with the approval of the South
Western Sydney Local Health District Human Research
Ethics Committee (HREC Reference: HREC/14/LPOOL/
186; project number 14/103). Surgical specimens were
collected from 265 patients who were treated with che-
moradiotherapy or neoadjuvant radiotherapy followed by
surgery for rectal cancer during the period 2000–2011.
Patients were treated with either a 50.4 Gy dose
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administered over 28 fractions or a 25 Gy dose of radio-
therapy administered over five treatment fractions; the
former also received 5-fluorouracil-based chemotherapy.
Surgery comprised of anterior or abdominoperineal re-
section, with total mesorectal excision. Follow-up in-
cluded clinic visits, blood tests, colonoscopy, and
imaging which were done at the discretion of the treat-
ing specialist.
Response and outcomes of interest
Short-term response to neoadjuvant radiotherapy was
measured by tumor regression grade (TRG) according to
the 7th edition of the American Joint Committee on
Cancer manual [26]. Variables included pathological
TNM stage, histological grade, age, sex, vascular inva-
sion, presence of tumor-infiltrating lymphocytes, peri-
neural invasion and treatment modality. TRG was
excluded as a variable because the sample set of re-
sponders (6/55, 10.9%) was too small for meaningful
statistical analysis. Parameters for long-term outcomes
were disease-free survival (DFS; time from diagnosis to
first recurrence) and OS (time from diagnosis to last
follow-up or death) (both DFS and OS determined by
Kaplan–Meir analysis).
Sample preparation and tissue microarrays
Preparation of tissue microarray (TMA) slides from arch-
ival tissue samples of pre- and post-operative rectal cancer
tissues from these patients has been described [25]. Tissue
samples for analysis were obtained from five sites (two
samples per site): tumor center (TC); invasive edge at
tumor periphery (TP); adjacent normal mucosa; nonadja-
cent normal mucosa; involved lymph nodes. Representa-
tive areas of tumor and normal tissue were identified by
microscopic analysis of H&E stained sections and used to
prepare TMA slides as previously reported (REF) using a
Beecher Manual Tissue Microarrayer (Beecher Instru-
ments Inc., Sun Prairie, WI, USA).
Immunohistochemical analysis
For immunohistochemistry, deparaffinization and anti-
gen retrieval were performed as described [25]. The
TMA slides were then incubated with mouse monoclo-
nal primary antibodies including anti-RAD50 [13B3/
2C6] (1:400 dilution, Abcam #ab89; Cambridge, UK),
anti-MRE11 (1:600 dilution, Abcam #ab214) and
anti-NBS1 (1:800 dilution, Novus Bioscience, NBP1–
06609, Littleton, CO, USA) antibodies for 60 min at
room temperature. Immunostaining of these samples for
the mismatch repair proteins MLH1, MSH2, MSH6 and
PMS2 has been described [25].
Samples were scored by two pathologists independ-
ently. Expression of the 3 MRN proteins was calculated
as the product of intensity of staining and percent posi-
tive cells to produce a weighted score ranging from 0 to
12 as previously described [24]. Samples were catego-
rized into a low (score range: 0–< 6) or high (score




Total, n 265 55
Age (median) 71 66
Sex
Male 176 (66.4) 37 (67.3)
Female 89 (33.6) 18 (32.7)
Tumor stage
T1–2 87/260 (33.4) 17/55 (30.9)
T3–4 173/260 (66.6) 38/55 (69.1)
Node stage
N0 140/259 (54.1) 29/55 (52.7)
N1–2 119/259 (45.9) 26/55 (47.3)
Metastasis stage
M0 223/240 (92.9) 53/54 (98.1)
M1 17/240 (7.1) 1/54 (1.9)
Grade
1–2 245/265 (92.5) 51/55 (92.7)
3 20/265 (7.5) 4/55 (7.3)
Vascular invasion
Absent 201/263 (76.4) 47/55 (85.5)
Present 62/263 (23.6) 8/55 (14.5)
Perineural invasion
Absent 220/263 (83.7) 41/55 (74.5)
Present 43/263 (16.3) 14/55 (25.5)
Radiotherapy
Total 77/246 (31.3) –
Neoadjuvant 55/77 (71.4) –
Adjuvant 22/77 (28.6) 0/55 (0)
Recurrence
Absent 131/213 (61.5) 25/46 (54.3)
Present 82/213 (28.5) 21/46 (45.7)
Tumor regression grade
0–1 (good response) – 6/55 (10.9)
2–3 (poor response) – 49/55 (89.1)
Table 2 Performance of the MRN three proteins combined classification models
Model Tumor Normal Sensitivity (%) Specificity (%) Overall (%) ROC-AUC
Combined TCa 262 258 89.0 77.2 83.1 0.870
Combined TPb 261 258 78.2 77.6 77.9 0.862
aTumor center; bTumor periphery
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range: 6–12) expression group. Assessment for the mis-
match repair proteins was based on positive or negative
staining for MLH1, MSH2, MSH6 and PMS2 irrespect-
ive of the proportion of cells stained.
Statistical analysis
SPSS for Windows 22.0 (IBM Corporation, Armonk, NY,
USA) was used for statistical analysis. Survival analysis was
conducted both on the entire cohort and, separately, on
patients who received preoperative radiotherapy. MRE11,
RAD50 and NBS1 expression were compared and com-
bined by binary logistic regression as described previously
[27]. Univariate and multivariate analyses of the combined
expression of the three proteins at the TC and TP were
performed using Kaplan–Meier curves and Cox’s propor-
tional hazards survival modeling. Covariates were sex, age,
TNM stage, histological grade, vascular invasion, perineu-
ral invasion, chemotherapy, and radiotherapy. Univariate
analysis was performed using the Mann–Whitney U test.
p < 0.05 was considered statistically significant.
Results
Study population
A total of 265 patients were included in this study; charac-
teristics of the studied cohort are listed in Table 1. This
cohort included 176 (66.4%) males, 89 (33.6%) females.
The median age was 71 years (range: 35–100 years). All
patients were followed for a median period of 3.16 years
(range: 0–12.6 years) with a median time to death after
surgery of 2.5 years (range 0–11.1 years). A cohort of 77
patients (31.3%) were treated with radiotherapy, with the
majority of these (55 patients; 71.4%) having received pre-
operative therapy.
Establishment of a putative biomarker panel of MRN
complex proteins
Expression levels of MRE11, RAD50 and NBS1 proteins
in the TC were tested using a forward and reverse binary
logistic regression analysis in an immunohistochemical
scoring data set from 262 tumor samples and 258 nor-
mal tissues. The average receiver operator characteristic
area under the curve (ROC-AUC) in the final biomarker
model was 0.870 for the combined expression of the
three MRN proteins. The expression of MRE11, RAD50
and NBS1 proteins in the TP (tumor, n = 261; normal, n
= 258) were also tested, resulting in an average
ROC-AUC of 0.862. For the MRN combined panel, the
sensitivity was 89.0% and specificity was 77.2% in the
TC, and was 78.2% and 77.6%, respectively, in the TP.
Overall biomarker accuracy when measured in TC was
83.1% and when measured in TP was 77.9% (Table 2).
Association between the MRN combined expression and
clinicopathological features
We investigated the association between the
three-protein combined expression level and clinico-
pathological characteristics as summarized in Table 3.
Representative immunohistochemical staining of high
and low MRN combined three-protein expression in
rectal cancer tissues is shown in Fig. 1. High MRN
Table 3 Associations between combined MRN expression in
the tumor center or periphery and clinicohistopathological data














Male 62.5 66.8 0.567 80.0 64.6 0.121
Female 37.5 33.2 20.0 35.4
Age
≤70 43.8 46.5 0.751 36.0 47.1 0.290
> 70 56.2 53.5 64.0 52.9
Tumor stage
T1–2 50.0 30.0 0.009* 44.0 32.5 0.246
T3–4 50.0 70.0 56.0 67.5
Node stage
Negative 60.0 53.1 0.395 52.0 54.5 0.811
Positive 40.0 46.9 48.0 45.5
Metastasis stage
M0 97.8 91.7 0.147 100 92.1 0.153
M1 2.2 8.3 0 7.9
Grade
1–2 93.8 92.2 0.707 88.0 92.9 0.376
3 6.2 7.8 12.0 7.1
Vascular invasion
Absent 82.6 75 0.27 84 75.5 0.343
Present 17.4 25 16 24.5
Perineural invasion
Absent 84.8 83.8 0.869 92 83.1 0.250
Present 15.2 16.2 8 16.9
Adjuvant therapy
No 70.0 69.4 0.945 52.4 71.4 0.072
Yes 30.0 30.6 47.6 28.6
Neoadjuvant therapy
No 65.2 80.9 0.021* 68 78 0.205
Yes 34.8 19.1 32 22
MSH6
Negative 0 100 0.518 0 100 0.663
Positive 17.3 82.7 8.7 91.3
PMS2
Negative 11.1 88.9 0.669 0 100 0.345
Positive 16.5 84.5 9.1 90.9
*p < 0.05 was considered significant
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complex protein expression levels in the TC were sig-
nificantly associated with histological tumor stage (P =
0.009). In a comparison of patients with low or high expres-
sion of MRN complex proteins, we did not observe signifi-
cant differences in age, sex, lymph node involvement,
metastasis, vascular invasion, or perineural invasion. Inter-
estingly, we found that expression levels of MRN complex
proteins were also significantly associated with preoperative
neoadjuvant therapy (P = 0.021), with patients receiving
neoadjuvant therapy more often having low combined
MRN expression.
We then examined the status of the MMR pathway
in patient samples by evaluating a possible associ-
ation of MMR protein expression with MRN com-
bined protein expression. All cases were positive for
MLH1 and MSH2 expression; none were classified as
MSI-high (MMR-negative). Expression of MSH6 and
PMS2 was absent in 0.8% (2/256) and 3.6% (9/252)
of cases, respectively, and expression of these pro-
teins was not significantly associated with expression
of MRN combined proteins in either TC or TP sam-
ples (Table 3).
Association between the MRN combined expression and
survival outcomes
Patients with high expression of MRN complex pro-
teins in the TC had significantly worse DFS (P =
0.021; Fig. 2a) and OS (P = 0.002; Fig. 2b) than pa-
tients with low expression. Significant differences in
survival were not seen between patients with high or
low expression of MRN complex proteins in the TP
(DFS, P = 0.646, Fig. 2c; OS, P = 0.251; Fig. 2d). In
addition, we also investigated clinical outcomes of
MRE11 and NBS1 protein expression in relation to
histological grade tumors. Interestingly, we found that
high MRE11 expression was associated with a worse over-
all survival when patients in the early/low-grade subgroup
were analyzed (P = 0.045, Additional file 1: Figure S1A).
However, a similar significant effect of high MRE11 ex-
pression on DFS was not seen in this same patient group
(data not shown). No significant relationship between
NBS1 expression and OS was identified in early/low-grade
tumors (Additional file 1: Figure S1C). In contrast, high
NBS1 expression was significantly associated with worse
overall survival in high-grade tumors (P = 0.045, Add-
itional file 1: Figure S1D), suggesting that both MRE11
and NBS1 may act as potential prognostic indicators in
different patient groups.
Using univariate Cox regression analysis, we found
that high combined expression of the three proteins
in the TC was significantly associated with reduced
DFS (hazard ratio [HR] = 2.069, 95% confidence inter-
val [CI] 1.102–3.882, P = 0.024; Table 4). Additionally,
multivariate Cox analysis demonstrated that MRN
complex expression (HR = 2.114, 95% CI 1.096–4.078,
P = 0.026) and perineural invasion (HR = 2.16, 95% CI
1.209–3.859, P = 0.009) remained significantly associ-
ated with a worse DFS (Table 4), implying that those




Fig. 1 Immunohistochemical staining of MRE11, RAD50 and NBS1 proteins. Staining for each protein was scored as high or low as described in
the Methods section. Representative examples of typical nuclear staining of MRE11 (a), RAD50 (b), and NBS1(c) scored as high expression in
tumor cells. Correspondingly, examples of those scored as low expression for MRE11 (d), RAD50 (e), and NBS1 (f) are shown (40× magnification)
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Correlation of the MRN combined expression with
neoadjuvant radiotherapy
Preoperative or neoadjuvant therapy is the standard
treatment for locally advanced rectal cancer [28]. In
this study, we examined the possible association be-
tween clinicopathological characteristics and survival
outcomes with preoperative expression of MRN com-
bined proteins in the 55 patients who had received
preoperative radiotherapy. Of 55 patients, 37 (67.3%)
were male and 18 (33.6%) were female (Table 1). In
the subgroup of patients who received neo-adjuvant
radiotherapy, higher combined expression of the
MRN complex proteins was significantly associated
with worse DFS (Fig. 3a, P = 0.024) and OS (Fig. 3b,
P = 0.028). Multivariate analysis in patients who re-
ceived preoperative radiotherapy revealed that vari-
ables negatively impacting OS included higher
histological grade (HR = 7.275, 95% CI 1.842–28.730,
P = 0.005), high expression of MRN complex proteins
(HR = 4.196, 95% CI 0.968–18.191, P = 0.045), and
male sex (HR = 3.017, 95% CI 1.199–7.592, P = 0.019)
(Table 5).
Prognostic implications of MRN complex proteins in
lymph node (LN)-positive subgroup
DFS of rectal cancer patients with high expression of the
MRN combined panel was significantly worse than that of
patients with low expression. Interestingly, when patients
were grouped according to LN involvement, high MRN
combined expression was associated with worse DFS and
OS in patients with LN-positive tumors (n = 119) (DFS, P
= 0.029, Fig. 3d; OS, P = 0.020; Fig. 3f) but not in those
with LN-negative tumors (n = 140) (DFS, P = 0.485, Fig.
3c; OS, P = 0.073, Fig. 3e). By multivariate Cox analysis in
the LN-positive subgroup, expression of the MRN com-
bined panel in the TC significantly correlated with DFS
(HR = 3.474, 95% CI 1.054–11.451, P = 0.041) (Table 4).
This suggests that the combined expression of the MRN
complex proteins may be associated with LN involvement
in relation to patient survival, and certainly this needs to
be verified in a larger sample set.
Discussion
Although neoadjuvant chemoradiotherapy has been
shown to improve outcomes over surgery alone [5–9],
A B
C D
Fig. 2 Association between MRN complex protein expression in the TC and TP and survival. a-d Kaplan–Meier survival analysis illustrating DFS
(a, c) and OS (b, d) of patients with high (green line) and low (blue line) MRN complex protein expression in the TC (a, b) and TP (c, d)
Ho et al. BMC Cancer  (2018) 18:869 Page 6 of 11
responses are variable between individuals and difficult
to predict [10, 11]. Methods for predicting response
would enable better treatment decisions to be made.
The TRG score, which reflects early response to treat-
ments such as radiotherapy, is significantly associated
with late response outcomes including recurrence and
survival [8–10]. However, there is a need for accurate,
reliable biomarkers of tumor radiosensitivity, to enable
better treatment decisions before any therapy is
administered. This could avoid unnecessary adverse ef-
fects [12, 13] in patients who are unlikely to benefit from
radiotherapy.
Efficient DNA damage detection, signaling, and repair
after radiotherapy can protect tumor cells against dam-
age. Additionally, avoidance of apoptosis or cell cycle ar-
rest can also allow tumor cells to proliferate even after
accumulating DNA damage from radiotherapy. These
processes can prolong tumor cell survival and promote




HR 95% CI P Value HR 95% P Value
MRN TCa
High 81.9 2.069 1.102–3.882 0.024* 2.114 1.096–4.078 0.026*
Low 18.1
Sex
Male 66.4 1.041 0.633–1.711 0.876
Female 33.6
Age
≤70 46.0 1.294 0.789–2.125 0.307
> 70 54.0
Tumor stage
T1–2 33.6 1.501 0.897–2.512 0.122
T3–4 66.4
Node stage
Negative 54.3 1.44 0.976–2.126 0.066
Positive 45.7
Grade
1–2 92.5 1.537 0.823–2.872 0.178
3 7.5
Vascular invasion
Absent 76.3 1.167 0.638–2.134 0.617
Present 23.7
Perineural invasion
Absent 84.0 2.334 1.310–4.157 0.004* 2.16 1.209–3.859 0.009*
Present 16.0
Adjuvant therapy
No 69.5 0.602 0.341–1.063 0.08
Yes 30.5
Neoadjuvant therapy
No 78.0 0.855 0.529–1.381 0.521
Yes 22.0
MRN TC by LNb
LN-negative 54.1 1.339 0.589–3.042 0.486
LN-positive 45.9 3.472 1.051–11.454 0.047*
HR hazard ratio, CI confidence interval, TC tumor center, LN lymph node
aThree marker combined expression in the tumor center; b denotes interaction
*p < 0.05 was considered significant
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poor clinical outcomes. Thus, DNA damage-related pro-
teins are potential biomarkers of tumor radiosensitivity.
The ten genes in the RSI are not directly involved in
DSB repair, but are often closely connected to DSB re-
pair in functional networks [15]. Of the dozens of mole-
cules studied that might predict survival after
preoperative therapy in colorectal cancer patients, many
are involved in apoptosis, cell cycle regulation, and DNA
damage [14]. Because of its well-known roles in
apoptosis and in linking genetic stability to the cell
cycle, the association of tumor suppressor p53 with




Fig. 3 Association between preoperative MRN protein expression in the TC and survival and combined MRN protein expression according to
preoperative radiotherapy and LN involvement. a, b Kaplan–Meier survival analysis illustrating DFS (a) and OS (b) in preoperative radiotherapy patient
groups with low (blue line) and high (green line) MRN complex panel expression. c-f Kaplan–Meier survival analysis illustrating DFS (c, d) and OS (e, f)
in patients with high (green line) and low (blue line) MRN combined expression, in LN-negative (c, e) and -positive (d, f) rectal cancers
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however, these studies have had very inconsistent
findings [14]. p21, which is a target of p53, has also
been implicated as a potential biomarker. In patients
with unresectable rectal cancer treated with pre-
operative chemoradiotherapy, p21 expression was as-
sociated with worse survival, even when adjusted for
tumor response [29]. Further studies are required to
identify and confirm reliable radiosensitivity bio-
markers, but DNA repair proteins remain attractive
targets.
Here, we established a biomarker panel comprising the
three proteins of the MRN complex, MRE11, RAD50 and
NBS1. To compare our previous study that identified the
combined expression of MRE11 and ATM as a prognostic
biomarker [24], the combined MRN expression had high
sensitivity and specificity in samples taken from both the
TC and TP. The sensitivity, specificity, and overall accur-
acy were higher for the combined MRN expression panel
than for combined MRE11/ATM expression, both in the
TC and TP. We found that high expression of the three
MRN complex proteins in the TC was significantly associ-
ated with DFS and OS in rectal cancer patients. Rectal
cancer patients with high expression of all three MRN
proteins are twice as likely to have a poorer DFS (HR =
2.114, 95% CI 1.096–4.078, P = 0.026) and four times
more likely to have poor OS (HR = 4.196, 95% CI 0.968–
18.191, P = 0.045) outcomes. Interestingly, none of the
other clinicopathologic variables were significantly associ-
ated with combined MRN expression. Therefore, this
panel appears to be specifically prognostic of DFS and OS.
When examining the subset of patients who received pre-
operative radiotherapy, the association between combined
MRN expression and outcome remained significant. It is
tempting to hypothesise that the prognostic value of this
panel may be related to tumor radiosensitivity, and future
research is warranted in a larger definitive cohort.
Interestingly, high MRN protein levels are associated
with better outcomes in some other cancer types. In
early breast cancer, patients with high MRN complex ex-
pression experienced the greatest reduction in recur-
rence from radiotherapy [30]. In two different studies of
bladder cancer patients, high MRE11 expression was as-
sociated with better cancer-specific survival in patients
who underwent radiotherapy rather than a cystectomy
[31, 32]. Therefore, the MRN complex may play a very
different role in cancers arising from different tissues.
Alternatively, the prognostic value of the MRN com-
plex expression may be dependent on certain combi-
nations of chemotherapy, radiotherapy, and surgery,
which vary between the treatment modalities pre-
ferred for different cancers.
When patients were classified by LN involvement, the
association of combined MRN complex protein expression
with DFS and OS was observed in LN-positive patients but
not LN-negative patients. The value of analyzing LN in-
volvement to predict outcomes has been established. In a
study of rectal cancer patients undergoing long-course
neoadjuvant chemoradiotherapy, combining LN involve-
ment with tumor grade was prognostic for survival after
treatment [33]. It is feasible that some biomarkers may
specifically predict outcomes in patients with LN involve-
ment or those without. Quintanal-Villalonga et al. [34]
found that a mutated version of the FGFR4 gene was asso-
ciated with OS only in LN-involved patients. Our findings
suggest that the potential prognostic value of the MRN ex-
pression panel may be related to the LN involvement of
the patient.
One mechanism that could lead to altered expression
of the MRN genes is defective MMR. Giannini et al. [35]
found that the MRE11 gene was mutated in
MMR-deficient tumors and cell lines, but not in those
with normal MMR function. All of the tumors we tested
expressed the two MMR proteins most frequently mu-
tated in MMR-deficient patients, MLH1 and MSH2. The
absence of MSH6 or PMS2 protein expression was not
significantly associated with combined MRN expression,
but this analysis was limited by the very small number
of cases lacking expression of either of these proteins.
Therefore, the mechanism underlying the prognostic
change in MRN expression identified here seems to be
independent of the MMR pathway, and is a subject for
further study.
The primary limitation of this study was the inability
to analyze the relationship of combined MRN expression
with tumor regression response. Only 10.6% of patients
were classified as responders to radiotherapy, repre-
sented by a TRG score of 0 or 1. Because increased
MRN protein expression was associated with worse out-
comes in rectal cancer patients, reducing MRN protein
expression or activity may possibly sensitize tumors to
radiotherapy. MRN complex inhibitors, including mirin
and telomelysin, have great radiosensitizing effects in
preclinical studies [36–38]. Telomelysin is undergoing
Phase I and II trials for use in patients with melanoma
(NCT03190824), esophageal cancer (NCT03213054),
and hepatocellular carcinoma (NCT02293850). The high
expression of MRN complex consitituents could be a
predictor for poor prognosis and chemoresistance in
Table 5 Multivariate analysis of combined MRN expression
association with overall survival in preoperative radiotherapy
patients
Multivariate
HR 95% P Value
MRN combined TC expression 4.196 0.968–18.191 0.045
Grade 7.275 1.842–28.730 0.005
Sex 3.017 1.199–7.592 0.019
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gastric cancer [39]. An adenovirus targeting RAD50 also
showed promise in sensitizing nasopharyngeal carcin-
oma cells to radiotherapy [40]. Alternatively, in patients
with higher MRN expression who are expected to have
worse outcomes, additional radiosensitizing treatments
could be used in combination with neoadjuvant radio-
therapy. Heat treatment, for example, shows good radio-
sensitizing effects in cells and is being explored in
cancer patients [41]. Dynlacht et al. [42] found that heat
radiosensitization was dependent on a functioning
MRE11 protein, further suggesting the utility of this
treatment in high MRN expression tumors.
Conclusions
The combined expression of the three MRN complex
subunits was significantly associated with OS and DFS
in rectal cancer patients, including those treated with
neoadjuvant radiotherapy. The findings in this study
support the proposal that high tissue expression levels of
the three MRN complex proteins are prognostic indica-
tors in rectal cancer and in response to preoperative
therapy. The association of MRN proteins with radiosen-
sitivity also suggests that the three MRN complex pro-
teins could be targets for the future development of
radiosensitizing agents.
Additional file
Additional file 1: Figure S1. Survival outcomes in relation to MRE11
and NBS1 protein expression in rectal cancer tissues. Kaplan-Meier ana-
lysis was performed to measure the overall survival (OS) for high (red line)
vs. low (blue line) MRE11, NBS1 protein expression in patients with rectal
cancer. (A-D) Comparison of survival curves according to histological
grade between MRE11 in low-grade (A, G1–2, n = 230) and high-grade (B,
G3, n = 19) subgroups; NBS1 in low vs. high grade (C, D) subgroups, re-
spectively. (PDF 163 kb)
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